Coronary artery diseasePredictors and Impact of Major Hemorrhage on Mortality Following Percutaneous Coronary Intervention from the REPLACE-2 Trial
Section snippets
Study protocol
The methods of REPLACE-2 have been reported.3 In this double-blind active-controlled trial, patients undergoing elective or urgent PCI were randomly assigned to 1 of 2 antithrombotic strategies: heparin (65-U/kg bolus, maximum 7,000 U) plus abciximab (0.25-mg/kg bolus, 0.125-μg/kg/min [maximum 10 μg/min] infusion for 12 hours) or eptifibatide (2 boluses of 180 μg/kg 10 minutes apart, 2.0-μg/kg/min infusion for 18 hours; heparin plus GPI group) versus bivalirudin (0.75-mg/kg bolus,
Baseline and periprocedural predictors of major hemorrhage
Of 6,001 patients from REPLACE-2, a total of 195 (3.2%) experienced a major hemorrhage. Univariable analysis indicated that a number of baseline and periprocedural factors were associated with major hemorrhage (Table 1). Multivariable analysis identified baseline predictors of major hemorrhage that included age ≥75 years, female gender, previous angina, anemia, and impaired creatinine clearance. A second multivariable analysis using periprocedural and baseline data showed that randomization to
Discussion
This comprehensive analysis of major hemorrhagic complications associated with elective or urgent PCI in the REPLACE-2 Trial indicated that (1) several baseline and periprocedural factors were independent predictors of major hemorrhage; (2) major hemorrhage was a powerful independent predictor of 1-year mortality; and (3) randomization to the heparin plus GPI group was an independent predictor of major hemorrhage.
This was the first prospective randomized trial to compare 2 active antithrombotic
References (22)
- et al.
Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions
Am J Cardiol
(2003) - et al.
Thrombolysis In Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
J Am Coll Cardiol
(1988) - et al.
Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I)
J Am Coll Cardiol
(1995) - et al.
Effect of anemia on hemmorrhagic complications and mortality in patients undergoing percutaneous coronary intervention
Am J Cardiol
(2007) - et al.
Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial
J Am Coll Cardiol
(2004) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
N Engl J Med
(1994)Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin TherapyNovel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial
Lancet
(2000)- et al.
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
JAMA
(2003) - et al.
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial
JAMA
(2004) - et al.
Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE)
Eur Heart J
(2003)
Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction anginaHirulog Angioplasty Study Investigators
N Engl J Med
Cited by (303)
Contemporary Management and Outcomes of Patients With High-Risk Pulmonary Embolism
2024, Journal of the American College of CardiologyIntracranial haemorrhage in acute myocardial infarction: A rare but dramatic complication
2023, International Journal of CardiologySex-Based Outcomes in Patients Undergoing WATCHMAN Device Implantation
2023, American Journal of CardiologyAnatomical Factors That Impede Using the Radial Artery Approach for Carotid Artery Revascularization
2022, World NeurosurgeryCitation Excerpt :As endovascular treatment of the craniocervical portion becomes more sophisticated, it is important to improve the treatment success rate and reduce complications. In percutaneous coronary intervention, the radial artery approach is superior to the femoral artery approach in preventing hemorrhagic complications at the access site and the incidence of myocardial infarctions, strokes, and contrast nephropathy.1-5 Although this approach is not suitable for large-bore devices, the access site involves less soft tissue, and hemostasis is easy to achieve by compressing the access site directly on the bone.
Meta-Analysis of Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease
2021, American Journal of Cardiology
REPLACE-2 was supported by a grant from The Medicines Company, Parsippany, New Jersey.